What are the side effects of Margituximab/Meganal?

Margetuximab is a modified monoclonal antibody against HER2-positive breast cancer and is a targeted immunotherapy drug. It blocks tumor growth signals by binding to the HER2 receptor on the surface of tumor cells and enhances the anti-tumor effect of the immune system, thereby delaying disease progression. Although the treatment is effective, patients may still experience certain side effects during use.

The most common side effects include infusion-related reactions such as fever, chills, fatigue, and mild rash, which usually occur with the first injection or after dose adjustments. In order to alleviate these symptoms, medical staff will give necessary preventive medications before infusion and closely monitor the patient's vital signs during the infusion process. Some patients may experience gastrointestinal reactions, such as nausea, vomiting, or diarrhea. Most of these symptoms can be relieved through dietary modification and supportive treatment.

In addition, a small number of patients may develop hematological abnormalities during long-term treatment, such as mild anemia or leukopenia, which require regular blood routine monitoring. Changes in cardiac function are also an issue that requires attention in HER2-targeted therapy. Especially for patients who have previously received cardiotoxic chemotherapy, their cardiac function should be evaluated before using margetuximab and followed up during the treatment.

Overall, the side effects of margetuximab are controllable and most are mild to moderate. Timely medical monitoring and standardized management can effectively reduce the risk. Patients should record their physical reactions during medication, review them regularly, and communicate with their attending doctors in a timely manner to ensure safe and sustained treatment effects. A correct understanding of drug side effects can help patients maintain confidence during treatment while achieving optimal clinical efficacy.

Reference materials:https://www.margenza.com/